Private equity consortium/Par Pharmaceutical

Target: Par Pharmaceutical
Buyer: Private equity consortium
Price: $1.9 billion
Closed: Sept. 28, 2012

This deal started when activist investor Ralph Whitworth decided the generics maker was worth a lot more than its valuation indicated. His Relational Investors increased its stake in Par, then told it to park itself on a corner with a For Sale sign in the window.

The company quickly picked up an offer. The Texas-based private equity group TPG agreed to pay $50 per share, a 37% premium, putting a total value of $1.9 billion on the company. Par wanted a couple of months to see if other buyers would check it out, and about 40 kicked the tires of the generics maker. Three even signed confidentiality agreements to get a closer look. But in the end, no auction materialized. TPG walked away with Par and Whitworth with some extra cash.

Private equity consortium/Par Pharmaceutical

Suggested Articles

Bluebird Bio has overcome a manufacturing hiccup that looked like it would delay its gene therapy launch in Europe until next year.

Lilly's top U.S. executive is on his way out. Enrique Conterno, who also heads up Lilly's global diabetes business, will step down at year's end.

GlaxoSmithKline, Pfizer, Sanofi and Boehringer Ingelheim are facing lawsuit claims that they failed to test for possible carcinogens in Zantac.